MD Medical Group Opens a New Clinic in Ryazan
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), Russia’s leading provider of private women’s and children’s healthcare, today announces the opening of a large medical centre in the Ryazan region.
“Mother and child Ryazan” is the first clinic in the Ryazan region to provide IVF services, and is also the only provider of other innovative services in the field of obstetrics and gynecology such as non-invasive genetic survey of pregnant women as well as modern methods of preimplantation genetic diagnostics. Unlike other medical facilities of the Group located in the regions of Russia, “Mother and child Ryazan” will provide numerous diagnostic and therapeutic services in pediatrics.
The new out-patient clinic is equipped with two operating rooms that enable it to perform endoscopic surgery using state-of-the-art equipment. “Mother and child Ryazan” also has a diagnostic centre, embryological laboratory, sperm bank and a cryo-depository. The clinic, with a total area of more than 1,000 sq m, aims to achieve full capacity, which would allow it to perform on an annual basis 480 IVF cycles and over 20,000 out-patient treatments.
Dr Mark Kurtser, Chairman of the Board of Directors of MD Medical Group, said:
"We are pleased to get off to a strong start in 2015 with the opening of our first clinic in Ryazan. I am certain that the people of Ryazan and nearby cities will value our unique and technologically advanced medical services, combined with the personalised, patient-centred approach from our high-quality team of doctors. “Of particular importance is the fact that we are the first company to offer IVF services in the Ryazan region, thereby strengthening still further our leading position in Russia’s IVF market. Previously, local residents had to travel to Moscow or other cities in order to get proper medical care in this field. With the opening of our clinic, these services are now available much closer to home. I believe we will be able to make a positive impact on the region’s demographics, thanks to our advanced medical care.”
For further information please contact:
|
Investors |
Media |
|
Elena Romanova
|
|
|
|
Consilium Strategic Communications London Chris Welsh / Matthew Neal Tel: +44 20 7309 5700 MDMG@em-comms.com |
About MD Medical Group
MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 23 modern healthcare facilities, including 4 hospitals and 19 outpatient clinics in Moscow, St. Petersburg, Ufa, Perm, Samara and Samara region, Novosibirsk, Irkutsk, Yaroslavl and Ryazan. In addition, 3 franchised outpatient clinics operate in Kyiv, Ukraine.
In 2014, there were 4,550 deliveries; IVF cycles amounted to 7,654. Number of outpatient treatments totalled 818,636 and number of in-patient days reached 35,900.
The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
Forward-Looking Statements:
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.